Skip to main content
Erschienen in: Hepatology International 4/2019

Open Access 06.06.2019 | Guidelines

Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update

verfasst von: Shiv Kumar Sarin, Ashok Choudhury, Manoj K. Sharma, Rakhi Maiwall, Mamun Al Mahtab, Salimur Rahman, Sanjiv Saigal, Neeraj Saraf, A. S. Soin, Harshad Devarbhavi, Dong Joon Kim, R. K. Dhiman, Ajay Duseja, Sunil Taneja, C. E. Eapen, Ashish Goel, Q. Ning, Tao Chen, Ke Ma, Z. Duan, Chen Yu, Sombat Treeprasertsuk, S. S. Hamid, Amna S. Butt, Wasim Jafri, Akash Shukla, Vivek Saraswat, Soek Siam Tan, Ajit Sood, Vandana Midha, Omesh Goyal, Hasmik Ghazinyan, Anil Arora, Jinhua Hu, Manoj Sahu, P. N. Rao, Guan H. Lee, Seng G. Lim, Laurentius A. Lesmana, Cosmas Rinaldi Lesmana, Samir Shah, V. G. Mohan Prasad, Diana A. Payawal, Zaigham Abbas, A. Kadir Dokmeci, Jose D. Sollano, Gian Carpio, Ananta Shresta, G. K. Lau, Md. Fazal Karim, Gamal Shiha, Rino Gani, Kemal Fariz Kalista, Man-Fung Yuen, Seema Alam, Rajeev Khanna, Vikrant Sood, Bikrant Bihari Lal, Viniyendra Pamecha, Ankur Jindal, V. Rajan, Vinod Arora, Osamu Yokosuka, Madunil A. Niriella, Hai Li, Xiaolong Qi, Atsushi Tanaka, Satoshi Mochida, Dominic Ray Chaudhuri, Ed Gane, Khin Maung Win, Wei Ting Chen, Mohd. Rela, Dharmesh Kapoor, Amit Rastogi, Pratibha Kale, Archana Rastogi, Chhagan Bihari Sharma, Meenu Bajpai, Virender Singh, Madhumita Premkumar, Sudhir Maharashi, A. Olithselvan, Cyriac Abby Philips, Anshu Srivastava, Surender K. Yachha, Zeeshan Ahmad Wani, B. R. Thapa, Anoop Saraya, Shalimar, Ashish Kumar, Manav Wadhawan, Subash Gupta, Kaushal Madan, Puja Sakhuja, Vivek Vij, Barjesh C. Sharma, Hitendra Garg, Vishal Garg, Chetan Kalal, Lovkesh Anand, Tanmay Vyas, Rajan P. Mathur, Guresh Kumar, Priyanka Jain, Samba Siva Rao Pasupuleti, Yogesh K. Chawla, Abhijit Chowdhury, Shahinul Alam, Do Seon Song, Jin Mo Yang, Eileen L. Yoon, APASL ACLF Research Consortium (AARC) for APASL ACLF working Party.

Erschienen in: Hepatology International | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up in 2004 on acute-on-chronic liver failure (ACLF) was published in 2009. With international groups volunteering to join, the “APASL ACLF Research Consortium (AARC)” was formed in 2012, which continued to collect prospective ACLF patient data. Based on the prospective data analysis of nearly 1400 patients, the AARC consensus was published in 2014. In the past nearly four-and-a-half years, the AARC database has been enriched to about 5200 cases by major hepatology centers across Asia. The data published during the interim period were carefully analyzed and areas of contention and new developments in the field of ACLF were prioritized in a systematic manner. The AARC database was also approached for answering some of the issues where published data were limited, such as liver failure grading, its impact on the ‘Golden Therapeutic Window’, extrahepatic organ dysfunction and failure, development of sepsis, distinctive features of acute decompensation from ACLF and pediatric ACLF and the issues were analyzed. These initiatives concluded in a two-day meeting in October 2018 at New Delhi with finalization of the new AARC consensus. Only those statements, which were based on evidence using the Grade System and were unanimously recommended, were accepted. Finalized statements were again circulated to all the experts and subsequently presented at the AARC investigators meeting at the AASLD in November 2018. The suggestions from the experts were used to revise and finalize the consensus. After detailed deliberations and data analysis, the original definition of ACLF was found to withstand the test of time and be able to identify a homogenous group of patients presenting with liver failure. New management options including the algorithms for the management of coagulation disorders, renal replacement therapy, sepsis, variceal bleed, antivirals and criteria for liver transplantation for ACLF patients were proposed. The final consensus statements along with the relevant background information and areas requiring future studies are presented here.
Literatur
1.
Zurück zum Zitat Sarin SK, Chandan K, Zaigham A, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2014;8:453–471CrossRefPubMed Sarin SK, Chandan K, Zaigham A, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2014;8:453–471CrossRefPubMed
2.
Zurück zum Zitat Sarin SK, Kumar A, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3(269):282 Sarin SK, Kumar A, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3(269):282
3.
Zurück zum Zitat Choudhury A, A Jindal SK, Sarin, for the APASL ACLF Working Party, et al. Liver failure determines the outcome in patients of Acute-on-Chronic Liver Failure (ACLF)-comparison of APASL-ACLF Research Consortium (AARC) and CLIF-SOFA model. Hepatol Int 2017;11(5):461–71PubMedCrossRef Choudhury A, A Jindal SK, Sarin, for the APASL ACLF Working Party, et al. Liver failure determines the outcome in patients of Acute-on-Chronic Liver Failure (ACLF)-comparison of APASL-ACLF Research Consortium (AARC) and CLIF-SOFA model. Hepatol Int 2017;11(5):461–71PubMedCrossRef
4.
Zurück zum Zitat Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490PubMedCrossRef Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490PubMedCrossRef
5.
Zurück zum Zitat O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273–275CrossRefPubMed O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273–275CrossRefPubMed
6.
Zurück zum Zitat Jalan R, Pavesi M, Wendon J, CANONIC Study Investigators; EASLCLIF Consortium, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol 2015;62(4):831–840CrossRefPubMed Jalan R, Pavesi M, Wendon J, CANONIC Study Investigators; EASLCLIF Consortium, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol 2015;62(4):831–840CrossRefPubMed
7.
Zurück zum Zitat Sen S, William R, Jalan R. The pathophysiological basis of acute-on- chronic liver failure. Liver 2002;22(Suppl 2):5–13CrossRefPubMed Sen S, William R, Jalan R. The pathophysiological basis of acute-on- chronic liver failure. Liver 2002;22(Suppl 2):5–13CrossRefPubMed
8.
Zurück zum Zitat Wlodzimirow KA, Eslami S, Abu-Hanna A, et al. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. Liver Int 2013;33(1):40–52CrossRefPubMed Wlodzimirow KA, Eslami S, Abu-Hanna A, et al. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. Liver Int 2013;33(1):40–52CrossRefPubMed
9.
Zurück zum Zitat Bajaj JS, Moreau R, Kamath PS, Vargas HE, Arroyo V, Reddy KR, Szabo G, Tandon P, Olson J, Karvellas C, Gustot T, Lai JC, Wong F. Acute-on-chronic liver failure: getting ready for prime time? Hepatology 2018;68(4):1621–1632 PMID:29689120 CrossRefPubMed Bajaj JS, Moreau R, Kamath PS, Vargas HE, Arroyo V, Reddy KR, Szabo G, Tandon P, Olson J, Karvellas C, Gustot T, Lai JC, Wong F. Acute-on-chronic liver failure: getting ready for prime time? Hepatology 2018;68(4):1621–1632 PMID:29689120 CrossRefPubMed
10.
Zurück zum Zitat Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy- definition, nomenclature, diagnosis and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna 1998. Hepatology 2002;25(3):716–721CrossRef Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy- definition, nomenclature, diagnosis and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna 1998. Hepatology 2002;25(3):716–721CrossRef
11.
Zurück zum Zitat Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426–1437CrossRefPubMed Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426–1437CrossRefPubMed
12.
Zurück zum Zitat Xu L, Tu Z, Xu G, et al. Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines: a novel mechanism of HBV reactivation following anticancer chemotherapy. Mol Med Rep 2014;9(4):1345–1350CrossRefPubMed Xu L, Tu Z, Xu G, et al. Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines: a novel mechanism of HBV reactivation following anticancer chemotherapy. Mol Med Rep 2014;9(4):1345–1350CrossRefPubMed
15.
Zurück zum Zitat Magalhaes RK, Ferreira D, Salgado M, et al. Hepatitis B virus reactivation after chemotherapy in an HIV positive patient. J Clin Gastroenterol 2013;47(6):565–566CrossRefPubMed Magalhaes RK, Ferreira D, Salgado M, et al. Hepatitis B virus reactivation after chemotherapy in an HIV positive patient. J Clin Gastroenterol 2013;47(6):565–566CrossRefPubMed
16.
Zurück zum Zitat Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002;51(4):597–599PubMedPubMedCentralCrossRef Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002;51(4):597–599PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab containing regimen. World J Hepatol 2013;5(11):612–662PubMedPubMedCentralCrossRef Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab containing regimen. World J Hepatol 2013;5(11):612–662PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Huang M, Huang L. Reactivation of hepatitis C viral infection after treatment with infliximab. J Clin Gastroenterol 2014;48(2):189–190CrossRefPubMed Huang M, Huang L. Reactivation of hepatitis C viral infection after treatment with infliximab. J Clin Gastroenterol 2014;48(2):189–190CrossRefPubMed
21.
Zurück zum Zitat Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, et al. Clinical presentation, outcome and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013;11(9):1174–1180CrossRefPubMed Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, et al. Clinical presentation, outcome and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013;11(9):1174–1180CrossRefPubMed
22.
Zurück zum Zitat Radha Krishna Y, Saraswat VA, Das K, Himanshu G, Yachha SK, Aggarwal R, Choudhari G. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int 2009;29(3):392–398CrossRefPubMed Radha Krishna Y, Saraswat VA, Das K, Himanshu G, Yachha SK, Aggarwal R, Choudhari G. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int 2009;29(3):392–398CrossRefPubMed
23.
Zurück zum Zitat Mahtab MA, Rahman S, Khan M, Karim MF. Hepatitis E virus is a leading cause of acute-on-chronic liver disease: experience from a tertiary center in Bangladesh. Hepatobiliary Pancreat Dis Int 2009;8(1):50–52PubMed Mahtab MA, Rahman S, Khan M, Karim MF. Hepatitis E virus is a leading cause of acute-on-chronic liver disease: experience from a tertiary center in Bangladesh. Hepatobiliary Pancreat Dis Int 2009;8(1):50–52PubMed
24.
Zurück zum Zitat Kumar M, Sharma BC, Sarin SK. Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus related chronic liver disease. J Gastroenterol Hepatol 2008;23(6):83–87CrossRef Kumar M, Sharma BC, Sarin SK. Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus related chronic liver disease. J Gastroenterol Hepatol 2008;23(6):83–87CrossRef
25.
Zurück zum Zitat Acharya SK, Sharma PK, Singh R, Mohanty SK, Madan K, Jha JK, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007;46:387–394CrossRef Acharya SK, Sharma PK, Singh R, Mohanty SK, Madan K, Jha JK, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007;46:387–394CrossRef
26.
Zurück zum Zitat Kim AY, Chung RT. Bacterial, Parasitic and Fungal infections of the liver, including liver abscess. In: Feldman M, Friedman L, Brandt LJ, editors. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 9th ed. Philadelphia: WB Saunders; 2010. 1351CrossRef Kim AY, Chung RT. Bacterial, Parasitic and Fungal infections of the liver, including liver abscess. In: Feldman M, Friedman L, Brandt LJ, editors. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 9th ed. Philadelphia: WB Saunders; 2010. 1351CrossRef
28.
Zurück zum Zitat Garg H, Kumar A, Garg V, Sharma P, Sharma BC, Sarin SK. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis 2012;44(2):166–171CrossRefPubMed Garg H, Kumar A, Garg V, Sharma P, Sharma BC, Sarin SK. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis 2012;44(2):166–171CrossRefPubMed
29.
Zurück zum Zitat Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghöner A, Vidacek D, Siewert E, et al. Patients with acute-on-chronic liver failure display “sepsis- like” immune paralysis. J Hepatol 2005;42(2):195–201CrossRefPubMed Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghöner A, Vidacek D, Siewert E, et al. Patients with acute-on-chronic liver failure display “sepsis- like” immune paralysis. J Hepatol 2005;42(2):195–201CrossRefPubMed
30.
Zurück zum Zitat Duseja A, Chawla YK, Dhiman RK, Kumar A, Choudhary N, Taneja S. Non-Hepatic insults are common precipitants in patients with acute-on-chronic liver failure. Dig Dis Sci 2010;55(11):3188–3192CrossRefPubMed Duseja A, Chawla YK, Dhiman RK, Kumar A, Choudhary N, Taneja S. Non-Hepatic insults are common precipitants in patients with acute-on-chronic liver failure. Dig Dis Sci 2010;55(11):3188–3192CrossRefPubMed
31.
Zurück zum Zitat Lo Re V III, Carbonari DM, Lewis JD, et al. Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. Am J Med 2016;129:283–291CrossRefPubMed Lo Re V III, Carbonari DM, Lewis JD, et al. Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. Am J Med 2016;129:283–291CrossRefPubMed
32.
Zurück zum Zitat Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study. Gastroenterology 2015;148:1340–1352PubMedPubMedCentralCrossRef Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study. Gastroenterology 2015;148:1340–1352PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008;48:1680–1689CrossRefPubMed Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008;48:1680–1689CrossRefPubMed
34.
Zurück zum Zitat Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis—a practical guide. Aliment Pharmacol Ther 2013;37:1132–1156CrossRefPubMed Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis—a practical guide. Aliment Pharmacol Ther 2013;37:1132–1156CrossRefPubMed
35.
Zurück zum Zitat Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007;37:410–415CrossRefPubMed Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007;37:410–415CrossRefPubMed
36.
Zurück zum Zitat Pais R, Rusu E, Ratziu V. The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. Clin Liver Dis 2014;18:165–178CrossRefPubMed Pais R, Rusu E, Ratziu V. The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. Clin Liver Dis 2014;18:165–178CrossRefPubMed
37.
Zurück zum Zitat Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. Aids 2007;21:1301–1308CrossRefPubMed Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. Aids 2007;21:1301–1308CrossRefPubMed
38.
Zurück zum Zitat Thulstrup AM, Molle I, Svendsen N, et al. Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based study. Epidemiol Infect 2000;124:221–225PubMedPubMedCentralCrossRef Thulstrup AM, Molle I, Svendsen N, et al. Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based study. Epidemiol Infect 2000;124:221–225PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Lin YT, Wu PH, Lin CY, et al. Cirrhosis as a risk factor for tuberculosis infection–a nationwide longitudinal study in Taiwan. Am J Epidemiol 2014;180:103–110CrossRefPubMed Lin YT, Wu PH, Lin CY, et al. Cirrhosis as a risk factor for tuberculosis infection–a nationwide longitudinal study in Taiwan. Am J Epidemiol 2014;180:103–110CrossRefPubMed
40.
Zurück zum Zitat Wang N-T, Huang Y-S, Lin M-H, Huang B, Perng C-L, Lin H-C. Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: systematic review and meta-analysis. J Chin Med Assoc 2016;79:368–374CrossRefPubMed Wang N-T, Huang Y-S, Lin M-H, Huang B, Perng C-L, Lin H-C. Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: systematic review and meta-analysis. J Chin Med Assoc 2016;79:368–374CrossRefPubMed
41.
Zurück zum Zitat Kim WS, Lee SS, Lee CM, Kim HJ, Ha CY, Kim HJ, et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis 2016;16:50PubMedPubMedCentralCrossRef Kim WS, Lee SS, Lee CM, Kim HJ, Ha CY, Kim HJ, et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis 2016;16:50PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Qin G, Shao JG, Zhu YC, et al. Population-representative incidence of acute-on-chronic liver failure. A prospective cross-sectional study. J Clin Gastroenterol 2016;50:670–675PubMedPubMedCentralCrossRef Qin G, Shao JG, Zhu YC, et al. Population-representative incidence of acute-on-chronic liver failure. A prospective cross-sectional study. J Clin Gastroenterol 2016;50:670–675PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Shi Y, Yang Y, Hu Y, et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology 2015;62:232–242CrossRefPubMed Shi Y, Yang Y, Hu Y, et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology 2015;62:232–242CrossRefPubMed
44.
Zurück zum Zitat Shalimar, Saraswat V, Singh SP, et al. Acute-on-chronic liver failure in India: the Indian National Association for Study of the Liver consortium experience. J Gastroenterol Hepatol 2016;31:1742–1749CrossRef Shalimar, Saraswat V, Singh SP, et al. Acute-on-chronic liver failure in India: the Indian National Association for Study of the Liver consortium experience. J Gastroenterol Hepatol 2016;31:1742–1749CrossRef
45.
Zurück zum Zitat Yeoman AD, O’Grady JG, Heneghan MA. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol 2014;61:876–882CrossRefPubMed Yeoman AD, O’Grady JG, Heneghan MA. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol 2014;61:876–882CrossRefPubMed
46.
Zurück zum Zitat Stravitz RT, Lefkowitch JH, Fontana RJ, Gershwin ME, Leung PS, Sterling RK, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011;53:517–526PubMedPubMedCentralCrossRef Stravitz RT, Lefkowitch JH, Fontana RJ, Gershwin ME, Leung PS, Sterling RK, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology 2011;53:517–526PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Anand L, Choudhury A, Bihari C, Sarin SK, for APASL ACLF (AARC) working party. Flare of Autoimmune Hepatitis causing acute on chronic liver failure (ACLF): diagnosis and response to corticosteroid therapy. Hepatology 2018. https://doi.org/10.1002/hep.30205 (Epub ahead of print, PMID: 30113706 ) CrossRef Anand L, Choudhury A, Bihari C, Sarin SK, for APASL ACLF (AARC) working party. Flare of Autoimmune Hepatitis causing acute on chronic liver failure (ACLF): diagnosis and response to corticosteroid therapy. Hepatology 2018. https://​doi.​org/​10.​1002/​hep.​30205 (Epub ahead of print, PMID: 30113706 ) CrossRef
48.
Zurück zum Zitat Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterol 2007;133:481–488CrossRef Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterol 2007;133:481–488CrossRef
49.
Zurück zum Zitat Amitrano L, Guardascione MA, Martino R, Manguso F, Menchise A, Balzano A. Hypoxic hepatitis occurring in cirrhosis after variceal bleeding: still a lethal disease. J Clin Gastroenterol 2012;46(7):608–612CrossRef Amitrano L, Guardascione MA, Martino R, Manguso F, Menchise A, Balzano A. Hypoxic hepatitis occurring in cirrhosis after variceal bleeding: still a lethal disease. J Clin Gastroenterol 2012;46(7):608–612CrossRef
50.
Zurück zum Zitat Bruns T, Zimmermann HW, Stallmach A. Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol 2014;20(10):2542–2554PubMedPubMedCentralCrossRef Bruns T, Zimmermann HW, Stallmach A. Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol 2014;20(10):2542–2554PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Kim RD, Kim JS, Watanabe G, Mohuczy D, Behrns KE. Liver regeneration and the atrophy-hypertrophy complex. Semin Interv Radiol 2008;25:92–103CrossRef Kim RD, Kim JS, Watanabe G, Mohuczy D, Behrns KE. Liver regeneration and the atrophy-hypertrophy complex. Semin Interv Radiol 2008;25:92–103CrossRef
52.
Zurück zum Zitat Langlet P, Escolano S, Valla D, Coste-Zeitoun D, Denie C, Mallet A, et al. Clinicopathological forms and prognostic index in Budd–Chiari syndrome. J Hepatol 2003;39:496–501CrossRefPubMed Langlet P, Escolano S, Valla D, Coste-Zeitoun D, Denie C, Mallet A, et al. Clinicopathological forms and prognostic index in Budd–Chiari syndrome. J Hepatol 2003;39:496–501CrossRefPubMed
53.
Zurück zum Zitat Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004;40:860–867CrossRefPubMed Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004;40:860–867CrossRefPubMed
54.
Zurück zum Zitat Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995;21(5):1238–1247PubMed Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995;21(5):1238–1247PubMed
55.
Zurück zum Zitat Kim MY, Cho MY, Baik SK, Park HJ, Jeon HK, Im CK, et al. Histological subclassification of cirrhosis using the Laennac fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol 2011;55(5):1004–1009CrossRefPubMed Kim MY, Cho MY, Baik SK, Park HJ, Jeon HK, Im CK, et al. Histological subclassification of cirrhosis using the Laennac fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol 2011;55(5):1004–1009CrossRefPubMed
56.
Zurück zum Zitat Rastogi A, Maiwall R, Bihari C, Ahuja A, Kumar A, Singh T, et al. Cirrhosis etiology and laennac staging system correlate with high portal pressure. Histopathology 2013;62(5):731–741CrossRefPubMed Rastogi A, Maiwall R, Bihari C, Ahuja A, Kumar A, Singh T, et al. Cirrhosis etiology and laennac staging system correlate with high portal pressure. Histopathology 2013;62(5):731–741CrossRefPubMed
57.
Zurück zum Zitat Libbrecht L, Desmet V, Van Damme B, Roskams T. Deep intralobular extension of human hepatic “progenitor cells” correlates with parenchymal inflammation in chronic viral hepatitis: can “progenitor cells” migrate? J Pathol 2000;192:373–378CrossRefPubMed Libbrecht L, Desmet V, Van Damme B, Roskams T. Deep intralobular extension of human hepatic “progenitor cells” correlates with parenchymal inflammation in chronic viral hepatitis: can “progenitor cells” migrate? J Pathol 2000;192:373–378CrossRefPubMed
58.
Zurück zum Zitat de Graaf EL, Kench J, Dilworth P, Shackel NA, Strasser S, Joseph D, et al. Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the donor risk index. J Gastroenterol Hepatol 2012;27(3):540–546CrossRefPubMed de Graaf EL, Kench J, Dilworth P, Shackel NA, Strasser S, Joseph D, et al. Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the donor risk index. J Gastroenterol Hepatol 2012;27(3):540–546CrossRefPubMed
59.
Zurück zum Zitat Gabrielli M, Moisan F, Vidal M, Duarte I, Jiménez M, Izquierdo G, et al. Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study. Ann Hepatol 2012;11(6):891–898CrossRefPubMed Gabrielli M, Moisan F, Vidal M, Duarte I, Jiménez M, Izquierdo G, et al. Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study. Ann Hepatol 2012;11(6):891–898CrossRefPubMed
60.
Zurück zum Zitat Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30(6):1356–1362CrossRefPubMed Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30(6):1356–1362CrossRefPubMed
61.
Zurück zum Zitat Loomba R, Sanyal A. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10(11):686–690CrossRefPubMed Loomba R, Sanyal A. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10(11):686–690CrossRefPubMed
62.
Zurück zum Zitat Laleman W, Verbeke L, Meersseman P, Wauters J, van Pelt J, Cassiman D, et al. Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol 2011;5(4):523–537CrossRefPubMed Laleman W, Verbeke L, Meersseman P, Wauters J, van Pelt J, Cassiman D, et al. Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol 2011;5(4):523–537CrossRefPubMed
63.
Zurück zum Zitat Rastogi A, Kumar A, Sakhuja P, Bihari C, Gondal R, Hissar S, et al. Liver histology as predictor of outcome in patients with acute-on-chronic liver failure (ACLF). Virchows Arch 2011;459(2):121–127CrossRefPubMed Rastogi A, Kumar A, Sakhuja P, Bihari C, Gondal R, Hissar S, et al. Liver histology as predictor of outcome in patients with acute-on-chronic liver failure (ACLF). Virchows Arch 2011;459(2):121–127CrossRefPubMed
64.
Zurück zum Zitat Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, et al. Transjugular liver biopsy–indications, adequacy, quality of specimens, and complications—a systematic review. J Hep 2007;47:284–294CrossRef Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, et al. Transjugular liver biopsy–indications, adequacy, quality of specimens, and complications—a systematic review. J Hep 2007;47:284–294CrossRef
65.
Zurück zum Zitat Myers RP, Elkashab M, Ma M, et al. Transient Elastography for noninvasive assessment of liver fibrosis: a multicenter Canadian study. Can J Gastroenterol 2010;24(11):661–670PubMedPubMedCentralCrossRef Myers RP, Elkashab M, Ma M, et al. Transient Elastography for noninvasive assessment of liver fibrosis: a multicenter Canadian study. Can J Gastroenterol 2010;24(11):661–670PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Kedarisetty CK, Bhardwaj A, Garg H, Wagle P, Sarin SK. Reduction in liver stiffness at one month is a predictor of survival in acute-on-chronic liver failure. In: Presented as poster at APASL annual conference 2014, Brisbane Kedarisetty CK, Bhardwaj A, Garg H, Wagle P, Sarin SK. Reduction in liver stiffness at one month is a predictor of survival in acute-on-chronic liver failure. In: Presented as poster at APASL annual conference 2014, Brisbane
67.
Zurück zum Zitat Jha AK, Nijhawan S, Rai RR, Nepalia S, Jain P, Suchismita A. Etiology, clinical profile and inhospital mortality of acute-on-chronic liver failure: a prospective study. Indian J Gastroenterol 2013;32(2):108–114CrossRefPubMed Jha AK, Nijhawan S, Rai RR, Nepalia S, Jain P, Suchismita A. Etiology, clinical profile and inhospital mortality of acute-on-chronic liver failure: a prospective study. Indian J Gastroenterol 2013;32(2):108–114CrossRefPubMed
68.
Zurück zum Zitat Seto WK, Lai CL, Yuen MF. Acute-on-chronic liver failure in chronic hepatitis B. J Gastroenterol Hepatol 2012;27(4):662–669CrossRefPubMed Seto WK, Lai CL, Yuen MF. Acute-on-chronic liver failure in chronic hepatitis B. J Gastroenterol Hepatol 2012;27(4):662–669CrossRefPubMed
69.
Zurück zum Zitat Adams LA, Lymp JF, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology 2005;129:113–121CrossRefPubMed Adams LA, Lymp JF, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology 2005;129:113–121CrossRefPubMed
70.
Zurück zum Zitat Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and natural history of nonalcoholic fatty liver disease. J Hepatol 2004;40:578–584CrossRefPubMed Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and natural history of nonalcoholic fatty liver disease. J Hepatol 2004;40:578–584CrossRefPubMed
71.
Zurück zum Zitat Bhala N, Angulo P, Van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, et al. The Natural history of Nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208–1216PubMedPubMedCentralCrossRef Bhala N, Angulo P, Van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, et al. The Natural history of Nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208–1216PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93(1):44–48CrossRefPubMed Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93(1):44–48CrossRefPubMed
73.
Zurück zum Zitat Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van Rensberg C, Kotze M. APRI: a simple bedside marker of advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J 2011;101(7):477–480PubMed Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van Rensberg C, Kotze M. APRI: a simple bedside marker of advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J 2011;101(7):477–480PubMed
74.
Zurück zum Zitat Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, Portal Hypertension Collaborative Group, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54:555–561PubMedPubMedCentralCrossRef Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, Portal Hypertension Collaborative Group, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54:555–561PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Duseja A, De A, Taneja S, Choudhury A, Devarbhavi H, Hu J, et al. Prevalence of metabolic risk factors and its impact on the severity and outcome of patients with alcohol related acute-on-chronic liver failure (ACLF— A case control study from the AARC data base. AASLD abstract. Hepatol 2018;S1 Duseja A, De A, Taneja S, Choudhury A, Devarbhavi H, Hu J, et al. Prevalence of metabolic risk factors and its impact on the severity and outcome of patients with alcohol related acute-on-chronic liver failure (ACLF— A case control study from the AARC data base. AASLD abstract. Hepatol 2018;S1
76.
Zurück zum Zitat Choudhury AK, Mahtab AM, Sarin SK, for ACLF Working Party. Acute on Chronic Liver Failure (ACLF) has a better long-term survival than Acute decompensation- a study of 4897 patients from APASL ACLF Research Consortium (AARC) with a follow-up of 5 years. AASLD abstract. Hepatol 2017;S1 Choudhury AK, Mahtab AM, Sarin SK, for ACLF Working Party. Acute on Chronic Liver Failure (ACLF) has a better long-term survival than Acute decompensation- a study of 4897 patients from APASL ACLF Research Consortium (AARC) with a follow-up of 5 years. AASLD abstract. Hepatol 2017;S1
77.
78.
Zurück zum Zitat Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010;59(11):1561–1569CrossRefPubMed Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010;59(11):1561–1569CrossRefPubMed
79.
Zurück zum Zitat Jalan R, Mookerjee RP. Acute-on-chronic liver failure: an early liver biopsy is essential? Gut 2010;59(11):1455–1456CrossRefPubMed Jalan R, Mookerjee RP. Acute-on-chronic liver failure: an early liver biopsy is essential? Gut 2010;59(11):1455–1456CrossRefPubMed
80.
Zurück zum Zitat Hoffman A, Rahman F, Prengel S, Schuchmann M, Gotz M, Moehler M, Galle PR, Li Z, Kalloo AN, Kiesslich R. Mini-laparoscopy in the endoscopy unit: safety and outcomes in over one thousand patients. World J Gastrointest Endosc 2011;3(1):6–10 PMID: 21258600 PubMedPubMedCentralCrossRef Hoffman A, Rahman F, Prengel S, Schuchmann M, Gotz M, Moehler M, Galle PR, Li Z, Kalloo AN, Kiesslich R. Mini-laparoscopy in the endoscopy unit: safety and outcomes in over one thousand patients. World J Gastrointest Endosc 2011;3(1):6–10 PMID: 21258600 PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010;59(11):1561–1569CrossRefPubMed Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010;59(11):1561–1569CrossRefPubMed
82.
Zurück zum Zitat Rastogi A, Maiwall R, Bihari C, Trehanpati N, Pamecha V, Sarin SK. Two-tier regenerative response in liver failure in humans. Virchows Arch 2014;464(5):565–573CrossRefPubMed Rastogi A, Maiwall R, Bihari C, Trehanpati N, Pamecha V, Sarin SK. Two-tier regenerative response in liver failure in humans. Virchows Arch 2014;464(5):565–573CrossRefPubMed
83.
Zurück zum Zitat Rastogi A, Bihari C, Maiwall R, Ahuja A, Sharma MK, Kumar A, Sarin SK. Hepatic stellate cells are involved in the pathogenesis of acute-on-chronic liver failure. Virchows Arch 2012;461(4):393–398CrossRefPubMed Rastogi A, Bihari C, Maiwall R, Ahuja A, Sharma MK, Kumar A, Sarin SK. Hepatic stellate cells are involved in the pathogenesis of acute-on-chronic liver failure. Virchows Arch 2012;461(4):393–398CrossRefPubMed
84.
Zurück zum Zitat Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC, et al. Granulocyte colony stimulating factor mobilizes CD 34 + cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012;142(3):505–512CrossRefPubMed Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC, et al. Granulocyte colony stimulating factor mobilizes CD 34 + cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012;142(3):505–512CrossRefPubMed
85.
Zurück zum Zitat Saxena P, Bihari C, Rastogi A, Agarwal S, Anand L, Sarin SK. Sonoclot signature analysis in patients with liver disease with conventional coagulation studies. Adv Hematol 2013;2013:23751 Saxena P, Bihari C, Rastogi A, Agarwal S, Anand L, Sarin SK. Sonoclot signature analysis in patients with liver disease with conventional coagulation studies. Adv Hematol 2013;2013:23751
86.
Zurück zum Zitat New York Heart Association Inc. New York Heart Association Classification of Heart Failure. Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. 6th ed. Boston: Little Brown; 1964. 114 New York Heart Association Inc. New York Heart Association Classification of Heart Failure. Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. 6th ed. Boston: Little Brown; 1964. 114
87.
Zurück zum Zitat Jeppesen JB, Mortensen C, Bendtsen F, Møller S. Lactate metabolism in chronic liver disease. Scand J Clin Lab Invest 2013;73(4):293–299CrossRefPubMed Jeppesen JB, Mortensen C, Bendtsen F, Møller S. Lactate metabolism in chronic liver disease. Scand J Clin Lab Invest 2013;73(4):293–299CrossRefPubMed
88.
Zurück zum Zitat Cardoso NM, Silva T, Basile-Filho A, Mente ED, Castro-e-Silva O. A new formula as a predictive score of post-liver transplan- tation outcome: postoperative MELD-lactate. Transpl Proc 2014;46(5):1407–1412CrossRef Cardoso NM, Silva T, Basile-Filho A, Mente ED, Castro-e-Silva O. A new formula as a predictive score of post-liver transplan- tation outcome: postoperative MELD-lactate. Transpl Proc 2014;46(5):1407–1412CrossRef
89.
Zurück zum Zitat Cordoba J, Ventura-Cots M, Simón-Talero M, Amorós A, Pavesi M, Vilstrup H, Angeli P, Domenicali M, Ginés P, Bernardi M, Arroyo V, CANONIC Study Investigators of EASL-CLIF Consortium. Char-acteristics, risk factors, and mortality of cirrhotic patients hospital-ized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol 2014;60(2):275–281CrossRefPubMed Cordoba J, Ventura-Cots M, Simón-Talero M, Amorós A, Pavesi M, Vilstrup H, Angeli P, Domenicali M, Ginés P, Bernardi M, Arroyo V, CANONIC Study Investigators of EASL-CLIF Consortium. Char-acteristics, risk factors, and mortality of cirrhotic patients hospital-ized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol 2014;60(2):275–281CrossRefPubMed
90.
Zurück zum Zitat Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003;31:1250–1256PubMedCrossRef Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003;31:1250–1256PubMedCrossRef
92.
Zurück zum Zitat Arvaniti V, D’Amico G, Fede G, Manousou P, Tsochatzis E, Plequezuelo M, Burroughs AK. Infections in patients with cirrhosis increase mortality four- fold and should be used in determining prognosis. Gastroenterology 2010;139:1246–1256CrossRefPubMed Arvaniti V, D’Amico G, Fede G, Manousou P, Tsochatzis E, Plequezuelo M, Burroughs AK. Infections in patients with cirrhosis increase mortality four- fold and should be used in determining prognosis. Gastroenterology 2010;139:1246–1256CrossRefPubMed
95.
Zurück zum Zitat Thabut D, Massard J, Moreau R, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007;46:1872–1882CrossRefPubMed Thabut D, Massard J, Moreau R, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007;46:1872–1882CrossRefPubMed
96.
Zurück zum Zitat Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care 2012;16(6):R227PubMedPubMedCentralCrossRef Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care 2012;16(6):R227PubMedPubMedCentralCrossRef
98.
Zurück zum Zitat Hotchkiss RS, Monneret G, Payen D. Sepsis induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13(12):862–874PubMedPubMedCentralCrossRef Hotchkiss RS, Monneret G, Payen D. Sepsis induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13(12):862–874PubMedPubMedCentralCrossRef
99.
Zurück zum Zitat Duseja A, Chawla YK, Dhiman RK, Kumar A, Choudhary N, Taneja S. Non-hepatic insults are common precipitants in patients with acute-on-chronic liver failure. Dig Dis Sci 2010;55(11):3188–3192CrossRefPubMed Duseja A, Chawla YK, Dhiman RK, Kumar A, Choudhary N, Taneja S. Non-hepatic insults are common precipitants in patients with acute-on-chronic liver failure. Dig Dis Sci 2010;55(11):3188–3192CrossRefPubMed
100.
Zurück zum Zitat Khanam A, Trehanpati N, Garg V, Kumar C, Garg H, Sharma BC, Sarin SK. Altered frequencies of dendritic cells and IFN- γ secreting T cells with granulocyte colony stimulating factor (GCSF) therapy in acute-on-chronic liver failure. Liver Int 2014;34(4):505–513CrossRefPubMed Khanam A, Trehanpati N, Garg V, Kumar C, Garg H, Sharma BC, Sarin SK. Altered frequencies of dendritic cells and IFN- γ secreting T cells with granulocyte colony stimulating factor (GCSF) therapy in acute-on-chronic liver failure. Liver Int 2014;34(4):505–513CrossRefPubMed
101.
Zurück zum Zitat Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Med 2000;26(Suppl 1):S124–S128CrossRefPubMed Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Med 2000;26(Suppl 1):S124–S128CrossRefPubMed
102.
Zurück zum Zitat Wasmuth HE, Kunz D, Yagmur E, Timmer- Stranghöner A, Vidacek D, Siewert E, et al. Patients with acute-on-chronic liver failure display “sepsis- like” immune paralysis. J Hepatol 2005;42(2):195–201CrossRefPubMed Wasmuth HE, Kunz D, Yagmur E, Timmer- Stranghöner A, Vidacek D, Siewert E, et al. Patients with acute-on-chronic liver failure display “sepsis- like” immune paralysis. J Hepatol 2005;42(2):195–201CrossRefPubMed
103.
Zurück zum Zitat Jindal A, Sarin SK. Acute Kidney Injury (AKI) at admission and its response to terlipressin as a predictor of mortality in patients with acute-on-chronic liver failure (ACLF). J Hepatol 2013;58(S1):S89CrossRef Jindal A, Sarin SK. Acute Kidney Injury (AKI) at admission and its response to terlipressin as a predictor of mortality in patients with acute-on-chronic liver failure (ACLF). J Hepatol 2013;58(S1):S89CrossRef
104.
105.
Zurück zum Zitat Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011;140:488–496CrossRefPubMed Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011;140:488–496CrossRefPubMed
106.
Zurück zum Zitat Stadlbauer V, Wright G, Banaji M, Mukhopadhyay A, Mookerjee R, Moore K, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008;134:111–119CrossRefPubMed Stadlbauer V, Wright G, Banaji M, Mukhopadhyay A, Mookerjee R, Moore K, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008;134:111–119CrossRefPubMed
108.
Zurück zum Zitat Cárdenas A, Ginès P. Acute-on-chronic liver failure: the kidneys. Curr Opin Crit Care 2011;17(2):184–189CrossRefPubMed Cárdenas A, Ginès P. Acute-on-chronic liver failure: the kidneys. Curr Opin Crit Care 2011;17(2):184–189CrossRefPubMed
109.
Zurück zum Zitat Maiwall R, Sarin SK, Kumar S, for APASL ACLF Research Consortium (AARC) working party, et al. Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. Liver Int 2017. https://doi.org/10.1111/liv.13443 (Epub ahead of print, PMID: 28393476) CrossRefPubMed Maiwall R, Sarin SK, Kumar S, for APASL ACLF Research Consortium (AARC) working party, et al. Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. Liver Int 2017. https://​doi.​org/​10.​1111/​liv.​13443 (Epub ahead of print, PMID: 28393476) CrossRefPubMed
110.
Zurück zum Zitat Maiwall R, Kumar S, Vashishtha C, Kumar M, Garg H, Nayak SL, et al. Acute kidney injury (AKI) in patients with Acute-on-chronic Liver failure (ACLF) is different from patients with cirrhosis. Hepatology 2013;58(4 Suppl):36A–91A Maiwall R, Kumar S, Vashishtha C, Kumar M, Garg H, Nayak SL, et al. Acute kidney injury (AKI) in patients with Acute-on-chronic Liver failure (ACLF) is different from patients with cirrhosis. Hepatology 2013;58(4 Suppl):36A–91A
111.
Zurück zum Zitat Wan ZH, Wang JJ, You SL, Liu HL, Zhu B, Zang H, et al. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol 2013;19(48):9432–9438PubMedPubMedCentralCrossRef Wan ZH, Wang JJ, You SL, Liu HL, Zhu B, Zang H, et al. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol 2013;19(48):9432–9438PubMedPubMedCentralCrossRef
112.
Zurück zum Zitat Xing T, Zhong L, Chen D, Peng Z. Experience of combined liver-kidney transplantation for acute-on-chronic liver failure with renal dysfunction. Transpl Proc 2013;45(6):2307–2313CrossRef Xing T, Zhong L, Chen D, Peng Z. Experience of combined liver-kidney transplantation for acute-on-chronic liver failure with renal dysfunction. Transpl Proc 2013;45(6):2307–2313CrossRef
113.
Zurück zum Zitat Maiwall R, Chandel SS, Wani Z, Kumar S, Sarin SK. SIRS at admission is a predictor of AKI development and mortality in hospitalized patients with severe alcoholic hepatitis. Dig Dis Sci 2016;61(3):920–929CrossRefPubMed Maiwall R, Chandel SS, Wani Z, Kumar S, Sarin SK. SIRS at admission is a predictor of AKI development and mortality in hospitalized patients with severe alcoholic hepatitis. Dig Dis Sci 2016;61(3):920–929CrossRefPubMed
114.
Zurück zum Zitat Arora V, Maiwall R, Choudhury A, Jain P, Kumar G, Sarin SK. Terlipressin is superior to Noradrenaline in the management of acute kidney injury (AKI) in patients with ACLF. Terlipressin is superior to Noradrenaline in the management of acute kidney injury (AKI) in patients with ACLF. J Hepatol 2017;66(1):S563 (in press) CrossRef Arora V, Maiwall R, Choudhury A, Jain P, Kumar G, Sarin SK. Terlipressin is superior to Noradrenaline in the management of acute kidney injury (AKI) in patients with ACLF. Terlipressin is superior to Noradrenaline in the management of acute kidney injury (AKI) in patients with ACLF. J Hepatol 2017;66(1):S563 (in press) CrossRef
115.
Zurück zum Zitat Gonwa TA, Wadei HM. The challenges of providing renal replacement therapy in decompensated liver cirrhosis. Blood Purif 2012;33:144–148CrossRefPubMed Gonwa TA, Wadei HM. The challenges of providing renal replacement therapy in decompensated liver cirrhosis. Blood Purif 2012;33:144–148CrossRefPubMed
116.
Zurück zum Zitat Cardoso FS, Gottfried M, Tujios S, Olson JC, Karvellas CJ, US Acute Liver Failure Study Group. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure. Hepatology 2017;31:15. https://doi.org/10.1002/hep.29488 (Epub ahead of print) CrossRef Cardoso FS, Gottfried M, Tujios S, Olson JC, Karvellas CJ, US Acute Liver Failure Study Group. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure. Hepatology 2017;31:15. https://​doi.​org/​10.​1002/​hep.​29488 (Epub ahead of print) CrossRef
117.
Zurück zum Zitat Donovan JP, Schafer DF, Shaw BW Jr, Sorrell MF. Cerebral edema and increased intracranial pressure in chronic liver disease. Lancet 1998;351:719–721CrossRefPubMed Donovan JP, Schafer DF, Shaw BW Jr, Sorrell MF. Cerebral edema and increased intracranial pressure in chronic liver disease. Lancet 1998;351:719–721CrossRefPubMed
118.
Zurück zum Zitat Gupta T, Dhiman RK, Ahuja CK, Agrawal S, Chopra M, Kalra N, Duseja A, Taneja S, Khandelwal N, Chawla Y. Characterization of cerebral edema in acute-on chronic liver failure. J Clin Exp Hepatol 2017;7:190–197.PubMedPubMedCentralCrossRef Gupta T, Dhiman RK, Ahuja CK, Agrawal S, Chopra M, Kalra N, Duseja A, Taneja S, Khandelwal N, Chawla Y. Characterization of cerebral edema in acute-on chronic liver failure. J Clin Exp Hepatol 2017;7:190–197.PubMedPubMedCentralCrossRef
119.
Zurück zum Zitat Butterworth RF, McPhail MJW. L-ornithine L-aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses. Drugs 2019;79(Suppl 1):31–37PubMedPubMedCentralCrossRef Butterworth RF, McPhail MJW. L-ornithine L-aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses. Drugs 2019;79(Suppl 1):31–37PubMedPubMedCentralCrossRef
120.
Zurück zum Zitat Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, et al. Infection and systemic inflammation, not ammonia, are associated with grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 2011;54:640–649CrossRefPubMed Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, et al. Infection and systemic inflammation, not ammonia, are associated with grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 2011;54:640–649CrossRefPubMed
121.
Zurück zum Zitat Guevara M, Baccaro ME, Torre A. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 2009;104:1382–1389CrossRefPubMed Guevara M, Baccaro ME, Torre A. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 2009;104:1382–1389CrossRefPubMed
122.
Zurück zum Zitat Verma A, Choudhury AK, Sarin SK, for APASL ACLF Working party, et al. Hepatic encephalopathy and ammonia can predict 28 day mortality in acute on chronic liver failure in a dynamic manner—results of multination study from APASAL-ACLF Research Consortium. AASLD abstract. Hepatol 2017;S1 Verma A, Choudhury AK, Sarin SK, for APASL ACLF Working party, et al. Hepatic encephalopathy and ammonia can predict 28 day mortality in acute on chronic liver failure in a dynamic manner—results of multination study from APASAL-ACLF Research Consortium. AASLD abstract. Hepatol 2017;S1
123.
Zurück zum Zitat Tripodi A, Primignani M, Chantarangkul V, Dell’Era A, Clerici M, de Franchis R, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009;137:2105–2111CrossRefPubMed Tripodi A, Primignani M, Chantarangkul V, Dell’Era A, Clerici M, de Franchis R, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009;137:2105–2111CrossRefPubMed
124.
Zurück zum Zitat Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006;44:1039–1046CrossRefPubMed Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006;44:1039–1046CrossRefPubMed
126.
Zurück zum Zitat Fisher C, Patel VC, Stoy SH, Singanayagam A, Adelmeijer J, Wendon J, et al. Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. J Crit Care 2018;43:54–60CrossRefPubMed Fisher C, Patel VC, Stoy SH, Singanayagam A, Adelmeijer J, Wendon J, et al. Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. J Crit Care 2018;43:54–60CrossRefPubMed
127.
Zurück zum Zitat Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol 2002;37:463–470CrossRefPubMed Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol 2002;37:463–470CrossRefPubMed
128.
Zurück zum Zitat Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood 1999;94:2569–2574CrossRefPubMed Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood 1999;94:2569–2574CrossRefPubMed
129.
Zurück zum Zitat Premkumar M, Saxena P, Mirza R, Baweja S, Sharma CB, Choudhury AK, Kedarisetty CK, Sarin SK. Assessment and relevance of coagulation disorders in patients with acute-on-chronic liver failure during Systemic Inflammatory Response (SIRS) and development of sepsis. Liv Int.2018. https://doi.org/10.1111/liv.14034 (accepted) CrossRef Premkumar M, Saxena P, Mirza R, Baweja S, Sharma CB, Choudhury AK, Kedarisetty CK, Sarin SK. Assessment and relevance of coagulation disorders in patients with acute-on-chronic liver failure during Systemic Inflammatory Response (SIRS) and development of sepsis. Liv Int.2018. https://​doi.​org/​10.​1111/​liv.​14034 (accepted) CrossRef
130.
131.
Zurück zum Zitat Premkumar M, Saxena P, Mirza R, Jain P, Bhatia P, Kumar G, Sukriti S, Bihari C, Choudhury A, Sarin SK. Heparin like effect increases risk of mortality and bleeding tendency in patients with severe alcoholic hepatitis during systemic Inflammatory Response (SIRS) and sepsis. AASLD abstract. Hepatol 2017;S1 Premkumar M, Saxena P, Mirza R, Jain P, Bhatia P, Kumar G, Sukriti S, Bihari C, Choudhury A, Sarin SK. Heparin like effect increases risk of mortality and bleeding tendency in patients with severe alcoholic hepatitis during systemic Inflammatory Response (SIRS) and sepsis. AASLD abstract. Hepatol 2017;S1
132.
Zurück zum Zitat Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003;349(13):1227–1235 PubMed PMID: 14507948 CrossRefPubMed Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003;349(13):1227–1235 PubMed PMID: 14507948 CrossRefPubMed
133.
Zurück zum Zitat Garg H, Kumar A, Garg V, Kumar M, Kumar R, Sharma BC, et al. Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute-on-chronic liver failure. J Gastroenterol Hepatol 2013;28(8):1361–137CrossRefPubMed Garg H, Kumar A, Garg V, Kumar M, Kumar R, Sharma BC, et al. Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute-on-chronic liver failure. J Gastroenterol Hepatol 2013;28(8):1361–137CrossRefPubMed
134.
Zurück zum Zitat Kumar V, Choudhury AK, Maiwall R, Mahtab MA, Rahman S, Alam MS, et al. Degree of hemodynamic derangements correlate with poor outcomes in acute on chronic liver failure (ACLF) patients. AASLD abstract. Hepatol 2018;S1 Kumar V, Choudhury AK, Maiwall R, Mahtab MA, Rahman S, Alam MS, et al. Degree of hemodynamic derangements correlate with poor outcomes in acute on chronic liver failure (ACLF) patients. AASLD abstract. Hepatol 2018;S1
135.
Zurück zum Zitat Choudhury AK, Sharma MK, Maiwal R, Jain P, Mahtab MA, Chawla YK, et al. Portal hemodynamics predicts the outcome in severe alcoholic hepatitis presenting as acute-on-chronic liver failure. J Hepatol 2016;S1:64–306 Choudhury AK, Sharma MK, Maiwal R, Jain P, Mahtab MA, Chawla YK, et al. Portal hemodynamics predicts the outcome in severe alcoholic hepatitis presenting as acute-on-chronic liver failure. J Hepatol 2016;S1:64–306
136.
Zurück zum Zitat Kainth S, Kumar M, Choudhury AK, Anand L, Jindal A, Kumar G, et al. Efficacy and safety of carvedilol in patients of acute-on-chronic liver failure with small or no esophageal varices—a placebo control open label randomised trial (NCT02583698). Hepatology 2017;66(Suppl 1):83A Kainth S, Kumar M, Choudhury AK, Anand L, Jindal A, Kumar G, et al. Efficacy and safety of carvedilol in patients of acute-on-chronic liver failure with small or no esophageal varices—a placebo control open label randomised trial (NCT02583698). Hepatology 2017;66(Suppl 1):83A
137.
Zurück zum Zitat Hari A, Nair HK, De Gottardi A, Baumgartner I, Dufour JF, Berzigotti A. Diagnostic hepatic haemodynamic techniques: safety and radiation exposure. Liver Int 2017;37(1):148–154CrossRefPubMed Hari A, Nair HK, De Gottardi A, Baumgartner I, Dufour JF, Berzigotti A. Diagnostic hepatic haemodynamic techniques: safety and radiation exposure. Liver Int 2017;37(1):148–154CrossRefPubMed
138.
Zurück zum Zitat Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol 2018;3(10):708–719CrossRefPubMed Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol 2018;3(10):708–719CrossRefPubMed
139.
Zurück zum Zitat Qi X, Li Z, Huang J, Zhu Y, Liu H, Zhou F, Liu C, Xiao C, Dong J, Zhao Y, Xu M, Xing S, Xu W, Yang C. Virtual portal pressure gradient from anatomic CT angiography. Gut 2015;64(6):1004–1005CrossRefPubMed Qi X, Li Z, Huang J, Zhu Y, Liu H, Zhou F, Liu C, Xiao C, Dong J, Zhao Y, Xu M, Xing S, Xu W, Yang C. Virtual portal pressure gradient from anatomic CT angiography. Gut 2015;64(6):1004–1005CrossRefPubMed
140.
Zurück zum Zitat Liu F, Ning Z, Liu Y, Liu D, Tian J, Luo H, An W, Huang Y, Zou J, Liu C, Liu C, Wang L, Liu Z, Qi R, Zuo C, Zhang Q, Wang J, Zhao D, Duan Y, Peng B, Qi X, Zhang Y, Yang Y, Hou J, Dong J, Li Z, Ding H, Zhang Y, Qi X. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. E BioMed 2018;36:151–158 Liu F, Ning Z, Liu Y, Liu D, Tian J, Luo H, An W, Huang Y, Zou J, Liu C, Liu C, Wang L, Liu Z, Qi R, Zuo C, Zhang Q, Wang J, Zhao D, Duan Y, Peng B, Qi X, Zhang Y, Yang Y, Hou J, Dong J, Li Z, Ding H, Zhang Y, Qi X. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. E BioMed 2018;36:151–158
141.
Zurück zum Zitat Arora V, Maiwal R, Thomas SS, RajanV, Ali R, Kumar G, Jain P, Sarin SK. Albumin decreases the incidence of paracentesis induced circulatory dysfunction with less than 5 litres of ascitic tap in acute on chronic liver failure (ACLF) patients: randomized controlled trial (NCT02467348). J Hepatol 2018;68(1):S42–S43CrossRef Arora V, Maiwal R, Thomas SS, RajanV, Ali R, Kumar G, Jain P, Sarin SK. Albumin decreases the incidence of paracentesis induced circulatory dysfunction with less than 5 litres of ascitic tap in acute on chronic liver failure (ACLF) patients: randomized controlled trial (NCT02467348). J Hepatol 2018;68(1):S42–S43CrossRef
142.
Zurück zum Zitat Cabrera J, Falcón L, Gorriz E, et al. Abdominal decompression plays a major role in early postparacentesis haemodynamic changes in cirrhotic patients with tense ascites Gut 2001;48:384–389 Cabrera J, Falcón L, Gorriz E, et al. Abdominal decompression plays a major role in early postparacentesis haemodynamic changes in cirrhotic patients with tense ascites Gut 2001;48:384–389
143.
Zurück zum Zitat Singh V, Singh A, Singh B, Vijayvergiya R, Sharma N, Ghai A, Bhalla A. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. Am J Gastroenterol 2013;108(4):560–567CrossRefPubMed Singh V, Singh A, Singh B, Vijayvergiya R, Sharma N, Ghai A, Bhalla A. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. Am J Gastroenterol 2013;108(4):560–567CrossRefPubMed
144.
Zurück zum Zitat Singh V, Kumar B, Nain CK, Singh B, Sharma N, Bhalla A, Sharma AK. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med 2006;260(1):62–68CrossRefPubMed Singh V, Kumar B, Nain CK, Singh B, Sharma N, Bhalla A, Sharma AK. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med 2006;260(1):62–68CrossRefPubMed
146.
147.
148.
Zurück zum Zitat Mathurin P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60:255–260CrossRefPubMed Mathurin P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60:255–260CrossRefPubMed
149.
Zurück zum Zitat Wong RJ, Aguilar M, Gish RG, Cheung R, Ahmed A. The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. Liver Transpl 2015;21:873–880.PubMedCrossRef Wong RJ, Aguilar M, Gish RG, Cheung R, Ahmed A. The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. Liver Transpl 2015;21:873–880.PubMedCrossRef
151.
152.
Zurück zum Zitat Yeoman AD, Westbrook RH, Portmann C, O’Grady OJ, Harrison PM, Heneghan MA. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatolog. 2011;53:926–934CrossRefPubMed Yeoman AD, Westbrook RH, Portmann C, O’Grady OJ, Harrison PM, Heneghan MA. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatolog. 2011;53:926–934CrossRefPubMed
153.
Zurück zum Zitat Wang J, Ma K, Han M, Guo W, Huang J, Yang D, Zhao X, Song J, Tian D, Qi J, Huang Y, Ning Q. Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: validation of the TPPM model. Hepatol Int 2014;8(1):64–71 (153n) CrossRefPubMed Wang J, Ma K, Han M, Guo W, Huang J, Yang D, Zhao X, Song J, Tian D, Qi J, Huang Y, Ning Q. Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: validation of the TPPM model. Hepatol Int 2014;8(1):64–71 (153n) CrossRefPubMed
154.
Zurück zum Zitat Ma K, Guo W, Han M, et al. Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model. Hepatol Int 2012;6(4):735–743 (153n) CrossRefPubMed Ma K, Guo W, Han M, et al. Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model. Hepatol Int 2012;6(4):735–743 (153n) CrossRefPubMed
155.
Zurück zum Zitat Tao C, Zhongyuan Y, Kumar A, Choudhury for APASL ACLF Research Consortium (AARC). Hepatology 2017; 67 ([ABSTRACT] Supple,ID#2776063.[155n]) Tao C, Zhongyuan Y, Kumar A, Choudhury for APASL ACLF Research Consortium (AARC). Hepatology 2017; 67 ([ABSTRACT] Supple,ID#2776063.[155n])
156.
Zurück zum Zitat Agrawal S, Duseja A, Gupta T, Dhiman RK, Chawla Y. Simple organ failure count versus CANONIC grading system for predicting mortality in acute-on-chronic liver failure. J Gastroenterol Hepatol 2015;30(3):575–581CrossRefPubMed Agrawal S, Duseja A, Gupta T, Dhiman RK, Chawla Y. Simple organ failure count versus CANONIC grading system for predicting mortality in acute-on-chronic liver failure. J Gastroenterol Hepatol 2015;30(3):575–581CrossRefPubMed
158.
Zurück zum Zitat Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int 2013;33(Suppl 1):164–175CrossRefPubMed Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int 2013;33(Suppl 1):164–175CrossRefPubMed
159.
Zurück zum Zitat Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. J Gastroenterol Hepatol 2010;25(3):583–590CrossRefPubMed Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. J Gastroenterol Hepatol 2010;25(3):583–590CrossRefPubMed
162.
Zurück zum Zitat Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. J Hepatol 2012;57(6):1336–1348CrossRefPubMed Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. J Hepatol 2012;57(6):1336–1348CrossRefPubMed
163.
Zurück zum Zitat Bahirwani R, Shaked O, Bewtra M, Forde K, Reddy KR. Acute-on-chronic liver failure before liver transplantation: impact on post transplant outcomes. Transplantation 2011;92(8):952–957CrossRefPubMed Bahirwani R, Shaked O, Bewtra M, Forde K, Reddy KR. Acute-on-chronic liver failure before liver transplantation: impact on post transplant outcomes. Transplantation 2011;92(8):952–957CrossRefPubMed
164.
Zurück zum Zitat Lin KH, Liu JW, Chen CL, Wang SH, Lin CC, Liu YW, et al. Impacts of pretransplant infections on clinical outcomes of patients with acute-on-chronic liver failure who received living donor liver transplantation. PLoS One 2013;8(9):e72893PubMedPubMedCentralCrossRef Lin KH, Liu JW, Chen CL, Wang SH, Lin CC, Liu YW, et al. Impacts of pretransplant infections on clinical outcomes of patients with acute-on-chronic liver failure who received living donor liver transplantation. PLoS One 2013;8(9):e72893PubMedPubMedCentralCrossRef
165.
Zurück zum Zitat Pamecha V, Kumar S, Bharathy KG. Liver transplantation in acute-on-chronic liver failure: challenges and an algorithm for patient selection and management. Hepatol Int. 2015. Pamecha V, Kumar S, Bharathy KG. Liver transplantation in acute-on-chronic liver failure: challenges and an algorithm for patient selection and management. Hepatol Int. 2015.
166.
167.
Zurück zum Zitat Chok KSh, Chan SC, Fung JY, Cheung TT, Chan AC, Fan ST, Lo CM. Survival outcomes of right-lobe living donor transplantation for patients with high model for end stage Liver Disease scores. Hepatobiliary Pancreat Dis Int 2013;12(3):256–262CrossRefPubMed Chok KSh, Chan SC, Fung JY, Cheung TT, Chan AC, Fan ST, Lo CM. Survival outcomes of right-lobe living donor transplantation for patients with high model for end stage Liver Disease scores. Hepatobiliary Pancreat Dis Int 2013;12(3):256–262CrossRefPubMed
168.
Zurück zum Zitat Choudhury AK, Sharma M, Mehtab M, Sarin SK, for APASL ACLF Working party, et al. The decision for liver transplant in acute-on-chronic liver failure (ACLF)—first week is the crucial period-analysis of the APASL ACLF Research Consortium (AARC) prospective data of 1021 patients. J Hepatol 2016;64:S1–S51CrossRef Choudhury AK, Sharma M, Mehtab M, Sarin SK, for APASL ACLF Working party, et al. The decision for liver transplant in acute-on-chronic liver failure (ACLF)—first week is the crucial period-analysis of the APASL ACLF Research Consortium (AARC) prospective data of 1021 patients. J Hepatol 2016;64:S1–S51CrossRef
169.
Zurück zum Zitat Gustot T, Fernandez J, Garcia E, for CANONIC Study Investigators of the EASL-CLIF Consortium, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62(1):243–252CrossRefPubMed Gustot T, Fernandez J, Garcia E, for CANONIC Study Investigators of the EASL-CLIF Consortium, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62(1):243–252CrossRefPubMed
170.
Zurück zum Zitat Wong RJ, Aguilar M, Gish RG, Cheung R, Ahmed A. The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. Liver Transpl 2015;21:873–880CrossRefPubMed Wong RJ, Aguilar M, Gish RG, Cheung R, Ahmed A. The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. Liver Transpl 2015;21:873–880CrossRefPubMed
171.
Zurück zum Zitat Staufer K, Roedl K, Kivaranovic D, Drolz A, Horvatits T, Rasoul-Rockenschaub S, Zauner C, Trauner M, Fuhrmann V. Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications. Liver Int 2017;37(6):843–850. https://doi.org/10.1111/liv.13389 (Epub 2017 Apr 5).CrossRefPubMed Staufer K, Roedl K, Kivaranovic D, Drolz A, Horvatits T, Rasoul-Rockenschaub S, Zauner C, Trauner M, Fuhrmann V. Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications. Liver Int 2017;37(6):843–850. https://​doi.​org/​10.​1111/​liv.​13389 (Epub 2017 Apr 5).CrossRefPubMed
172.
Zurück zum Zitat Cheng CH, Lee CF, Soong RS, Wu TH, Chan KM, Chou HS, Wu TJ, Yu MC, Lee WC. Risk factors and clinical outcomes of ventilator-associated pneumonia in patients on the liver transplant waiting list. Transpl Proc. 2012;44(3):762–4.CrossRef Cheng CH, Lee CF, Soong RS, Wu TH, Chan KM, Chou HS, Wu TJ, Yu MC, Lee WC. Risk factors and clinical outcomes of ventilator-associated pneumonia in patients on the liver transplant waiting list. Transpl Proc. 2012;44(3):762–4.CrossRef
173.
Zurück zum Zitat Moon DB, Lee SG, Kang WH, Song GW, Jung DH, Park GC, Cho HD, Jwa EK, Kim WJ, Ha TY, Kim HJ. Adult living donor liver transplantation for acute-on-chronic liver failure in high- model for end-stage liver disease score patients. Am J Transpl 2017;17(7):1833–1842 (PMID: 28097804-64) CrossRefPubMed Moon DB, Lee SG, Kang WH, Song GW, Jung DH, Park GC, Cho HD, Jwa EK, Kim WJ, Ha TY, Kim HJ. Adult living donor liver transplantation for acute-on-chronic liver failure in high- model for end-stage liver disease score patients. Am J Transpl 2017;17(7):1833–1842 (PMID: 28097804-64) CrossRefPubMed
178.
Zurück zum Zitat Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002;20:252–261CrossRefPubMed Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002;20:252–261CrossRefPubMed
179.
Zurück zum Zitat Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007;46(6):1853–1862CrossRefPubMed Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007;46(6):1853–1862CrossRefPubMed
180.
Zurück zum Zitat Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013;57:1153–1162CrossRefPubMed Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013;57:1153–1162CrossRefPubMed
181.
Zurück zum Zitat Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012;142:782–789CrossRefPubMed Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012;142:782–789CrossRefPubMed
182.
Zurück zum Zitat Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277–286CrossRefPubMed Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277–286CrossRefPubMed
183.
Zurück zum Zitat Catalina MV, Barrio J, Anaya F, Salcedo M, Rincón D, Clemente G, Bañares R. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int 2003;23(Suppl 3):39–43CrossRefPubMed Catalina MV, Barrio J, Anaya F, Salcedo M, Rincón D, Clemente G, Bañares R. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int 2003;23(Suppl 3):39–43CrossRefPubMed
184.
Zurück zum Zitat Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006;10:R108PubMedPubMedCentralCrossRef Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006;10:R108PubMedPubMedCentralCrossRef
185.
Zurück zum Zitat Guo LM, Liu JY, Xu DZ, Li BS, Han H, Wang LH, et al. Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int 2003;23(Suppl 3):16–20CrossRefPubMed Guo LM, Liu JY, Xu DZ, Li BS, Han H, Wang LH, et al. Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int 2003;23(Suppl 3):16–20CrossRefPubMed
186.
Zurück zum Zitat Atienza Merino G. Evaluation of extracorporeal liver support systems in thetreatment of liver failure: a systematic review. Gastroenterol Hepatol 2010;33(5):352–362CrossRefPubMed Atienza Merino G. Evaluation of extracorporeal liver support systems in thetreatment of liver failure: a systematic review. Gastroenterol Hepatol 2010;33(5):352–362CrossRefPubMed
187.
Zurück zum Zitat Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003;289(2):217–222CrossRefPubMed Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003;289(2):217–222CrossRefPubMed
188.
Zurück zum Zitat Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol 2016;64(1):69–78 (PMID: 26325537) CrossRefPubMed Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol 2016;64(1):69–78 (PMID: 26325537) CrossRefPubMed
189.
Zurück zum Zitat Ling Q, Xu X, Wei Q, Liu X, Guo H, Zhuang L, et al. Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure. PLoS One 2012;7(1):e30322PubMedPubMedCentralCrossRef Ling Q, Xu X, Wei Q, Liu X, Guo H, Zhuang L, et al. Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure. PLoS One 2012;7(1):e30322PubMedPubMedCentralCrossRef
190.
Zurück zum Zitat Xu X, Liu X, Ling Q, Wei Q, Liu Z, Xu X, et al. Artificial liver support system combined with liver transplantation in treatment of patients with acute-on-chronic liver failure. PLoS One 2013;8(3):e58738PubMedPubMedCentralCrossRef Xu X, Liu X, Ling Q, Wei Q, Liu Z, Xu X, et al. Artificial liver support system combined with liver transplantation in treatment of patients with acute-on-chronic liver failure. PLoS One 2013;8(3):e58738PubMedPubMedCentralCrossRef
191.
Zurück zum Zitat Duan XZ, Liu FF, Tong JJ, Yang HZ, Chen J, Liu XY, et al. Granulocyte colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol 2013;19:1104–1110PubMedPubMedCentralCrossRef Duan XZ, Liu FF, Tong JJ, Yang HZ, Chen J, Liu XY, et al. Granulocyte colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol 2013;19:1104–1110PubMedPubMedCentralCrossRef
192.
Zurück zum Zitat Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: from liver transplantation to cell factory. J Hepatol 2015;62(1S):S157–S169CrossRefPubMed Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: from liver transplantation to cell factory. J Hepatol 2015;62(1S):S157–S169CrossRefPubMed
193.
Zurück zum Zitat Liao X, AnCheng JY, Zhou QJ, Liao C. Therapeutic effect of autologous bone marrow-derived liver stem cells transplantation in hepatitis B virus-induced liver cirrhosis. Hepatogastroenterology 2013;60(123):406–409PubMed Liao X, AnCheng JY, Zhou QJ, Liao C. Therapeutic effect of autologous bone marrow-derived liver stem cells transplantation in hepatitis B virus-induced liver cirrhosis. Hepatogastroenterology 2013;60(123):406–409PubMed
194.
Zurück zum Zitat Di Campli C, Zocco MA, Saulnier N, et al. Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Dig Liver Dis 2007;39:1071–1076CrossRefPubMed Di Campli C, Zocco MA, Saulnier N, et al. Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Dig Liver Dis 2007;39:1071–1076CrossRefPubMed
195.
Zurück zum Zitat Singh V, Sharma AK, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol 2014;109:1417–1423CrossRefPubMed Singh V, Sharma AK, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol 2014;109:1417–1423CrossRefPubMed
196.
Zurück zum Zitat Kedarisetty CK, Anand L, Bhatia V, Sarin SK. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology 2015;148(7):1362.e7–1370.e7CrossRef Kedarisetty CK, Anand L, Bhatia V, Sarin SK. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology 2015;148(7):1362.e7–1370.e7CrossRef
197.
Zurück zum Zitat Meng F, Francis H, Glaser S, Alpini G. Role of stem cell factor and granulocyte colony-stimulating factor in remodeling during liver regeneration. Hepatology 2012;55(1):209–221PubMedPubMedCentralCrossRef Meng F, Francis H, Glaser S, Alpini G. Role of stem cell factor and granulocyte colony-stimulating factor in remodeling during liver regeneration. Hepatology 2012;55(1):209–221PubMedPubMedCentralCrossRef
198.
Zurück zum Zitat Pusic I, Di Persio JF. Update on clinical experience with amd3100, an sdf-1/cxcl12-cxcr4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol 2010;17:319–326CrossRefPubMed Pusic I, Di Persio JF. Update on clinical experience with amd3100, an sdf-1/cxcl12-cxcr4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol 2010;17:319–326CrossRefPubMed
200.
Zurück zum Zitat Lal J, Thapa BR, Rawal P, Ratho RK, Singh K. Predictors of outcome in acute-on-chronic liver failure in children. Hepatol Int 2011;5:693–697CrossRefPubMed Lal J, Thapa BR, Rawal P, Ratho RK, Singh K. Predictors of outcome in acute-on-chronic liver failure in children. Hepatol Int 2011;5:693–697CrossRefPubMed
201.
Zurück zum Zitat Jagadisan B, Srivastava A, Yachha SK, Poddar U. Acute-on-chronic liver disease in children from the developing world: recognition and prognosis. J Pediatr Gastroenterol Nutr 2012;54:77–82CrossRefPubMed Jagadisan B, Srivastava A, Yachha SK, Poddar U. Acute-on-chronic liver disease in children from the developing world: recognition and prognosis. J Pediatr Gastroenterol Nutr 2012;54:77–82CrossRefPubMed
202.
Zurück zum Zitat Lal BB, Sood V, Khanna R, Alam S. How to identify the need for liver transplantation in pediatric acute-on-chronic liver failure? Hepatol Int. 2018;12(6):552–9.CrossRefPubMed Lal BB, Sood V, Khanna R, Alam S. How to identify the need for liver transplantation in pediatric acute-on-chronic liver failure? Hepatol Int. 2018;12(6):552–9.CrossRefPubMed
203.
Zurück zum Zitat Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006;148:652–658PubMedPubMedCentralCrossRef Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006;148:652–658PubMedPubMedCentralCrossRef
Metadaten
Titel
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update
verfasst von
Shiv Kumar Sarin
Ashok Choudhury
Manoj K. Sharma
Rakhi Maiwall
Mamun Al Mahtab
Salimur Rahman
Sanjiv Saigal
Neeraj Saraf
A. S. Soin
Harshad Devarbhavi
Dong Joon Kim
R. K. Dhiman
Ajay Duseja
Sunil Taneja
C. E. Eapen
Ashish Goel
Q. Ning
Tao Chen
Ke Ma
Z. Duan
Chen Yu
Sombat Treeprasertsuk
S. S. Hamid
Amna S. Butt
Wasim Jafri
Akash Shukla
Vivek Saraswat
Soek Siam Tan
Ajit Sood
Vandana Midha
Omesh Goyal
Hasmik Ghazinyan
Anil Arora
Jinhua Hu
Manoj Sahu
P. N. Rao
Guan H. Lee
Seng G. Lim
Laurentius A. Lesmana
Cosmas Rinaldi Lesmana
Samir Shah
V. G. Mohan Prasad
Diana A. Payawal
Zaigham Abbas
A. Kadir Dokmeci
Jose D. Sollano
Gian Carpio
Ananta Shresta
G. K. Lau
Md. Fazal Karim
Gamal Shiha
Rino Gani
Kemal Fariz Kalista
Man-Fung Yuen
Seema Alam
Rajeev Khanna
Vikrant Sood
Bikrant Bihari Lal
Viniyendra Pamecha
Ankur Jindal
V. Rajan
Vinod Arora
Osamu Yokosuka
Madunil A. Niriella
Hai Li
Xiaolong Qi
Atsushi Tanaka
Satoshi Mochida
Dominic Ray Chaudhuri
Ed Gane
Khin Maung Win
Wei Ting Chen
Mohd. Rela
Dharmesh Kapoor
Amit Rastogi
Pratibha Kale
Archana Rastogi
Chhagan Bihari Sharma
Meenu Bajpai
Virender Singh
Madhumita Premkumar
Sudhir Maharashi
A. Olithselvan
Cyriac Abby Philips
Anshu Srivastava
Surender K. Yachha
Zeeshan Ahmad Wani
B. R. Thapa
Anoop Saraya
Shalimar
Ashish Kumar
Manav Wadhawan
Subash Gupta
Kaushal Madan
Puja Sakhuja
Vivek Vij
Barjesh C. Sharma
Hitendra Garg
Vishal Garg
Chetan Kalal
Lovkesh Anand
Tanmay Vyas
Rajan P. Mathur
Guresh Kumar
Priyanka Jain
Samba Siva Rao Pasupuleti
Yogesh K. Chawla
Abhijit Chowdhury
Shahinul Alam
Do Seon Song
Jin Mo Yang
Eileen L. Yoon
APASL ACLF Research Consortium (AARC) for APASL ACLF working Party.
Publikationsdatum
06.06.2019
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 4/2019
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-019-09946-3

Weitere Artikel der Ausgabe 4/2019

Hepatology International 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.